WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022

/PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Related Keywords

Germany ,China ,Wuxi ,Jiangsu ,Lingang ,Jiangxi ,Shanghai ,Hong Kong ,United States ,America ,Asia Pacific ,National Medical Products Administration ,Quarter Report Of The Company ,Accounting Standard For Business Enterprises ,Manufacturing Organization ,Stock Exchange Of Hong Kong ,Modalities Related Services ,Site Management Organization ,Shanghai Stock Exchange ,Owners Of The Company ,Contract Research ,Lab Testing Services Drives Steady Growth ,International Financial Reporting Standards ,Profit Attributable ,Turned Positive ,Grew Strongly ,Wuxi Apptec ,Quarter Report ,Stock Exchange ,Accounting Standard ,Business Enterprises ,Contract Testing ,Reporting Period ,Model Drives Steady Growth ,Continuous Expansion ,New Modalities Related Services ,Wuxi Chemistry ,Lab Testing Services Drives Steady ,Wuxi Testing ,Strong Contribution ,New Modalities Related ,Wuxi Biology ,Model Drives ,Shanghai Lingang ,Biological License Application ,Tumor Infiltrating Lymphocyte ,Lenti Viral Vector ,Pre Approval Inspection ,Drug Inspection ,First Year ,Receive New Drug Application ,New Drugs Developed ,Trial Approvals ,Financial Position ,Net Profit Attributable ,North America ,